Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL834671 | 1.00 | KDR (0.60) | KDRPDGFRBMAPTSMN1; SMN2NPC1 | |
| SCHEMBL834924 | 0.92 | KDR (0.50) | KDRPDGFRBMAPTNPC1RAB9A | |
| SCHEMBL834925 | 0.92 | KDR (0.50) | KDRPDGFRBMAPTNPC1RAB9A | |
| SCHEMBL3468670 | 0.90 | KDR (0.58) | KDRPDGFRBMAPT | |
| SCHEMBL832926 | 0.90 | KDR (0.57) | KDRPDGFRBMAPT | |
| SCHEMBL834939 | 0.88 | KDR (0.54) | KDRPDGFRBMAPTHPGD | |
| SCHEMBL834938 | 0.88 | KDR (0.54) | KDRPDGFRBMAPTHPGD | |
| SCHEMBL836264 | 0.87 | KDR (0.61) | KDRPDGFRBSMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL868405 | 0.86 | SMN1; SMN2 (0.47) | KDRPDGFRBMAPTSMN1; SMN2NPC1 | |
| SCHEMBL833863 | 0.85 | KDR (0.55) | KDRPDGFRBMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915443-B2 | Sulfoximines as kinase inhibitors | ALLERGAN, INC. (US) | 2011-03-29 | — | — | US | claimed |
| EP-2099757-A2 | SULFOXIMINES AS KINASE INHIBITORS | Allergan, Inc. (US) | 2009-09-16 | — | — | EP | claimed |
| US-20090099181-A1 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. | 2009-04-16 | — | — | US | claimed |
| WO-2008061236-A2 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2008-05-22 | — | — | WO | claimed |
| EP-2099757-B1 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8383825-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120207810-A1 | Kinase Inhibitors | SPADA LON T (US) | 2012-08-16 | — | — | US | disclosed |
| US-8143410-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110263611-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2011-10-27 | — | — | US | disclosed |
| US-7915443-B2 | Sulfoximines as kinase inhibitors | ALLERGAN, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| WO-2010078393-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| EP-2099757-A2 | SULFOXIMINES AS KINASE INHIBITORS | Allergan, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090196906-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090099181-A1 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2008061236-A2 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263611-A1 | Kinase Inhibitors | PTK2, MAP3K6, MAP3K20 | KDR 51/4885PDGFRB 368/4885MAPT 1650/4885 |
| US-20120207810-A1 | Kinase Inhibitors | PTK2, MAP3K6, MAP3K20 | KDR 51/4885PDGFRB 368/4885MAPT 1650/4885 |
| US-20090196906-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | KDR 51/4885PDGFRB 368/4885MAPT 1650/4885 |
| US-20090099181-A1 | SULFOXIMINES AS KINASE INHIBITORS | SRC, PTK2B, TYRO3 | KDR 321/4885PDGFRB 409/4885MAPT 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.